Breast MR imaging

Body MR Imaging at 3 Tesla

Volumn 9780521194860, Issue , 2011, Pages 26-33

  Partridge, Savannah C ^a   Rahbar, Habib ^a   Lehman, Constance D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DIAGNOSIS; DISEASES; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; SIGNAL TO NOISE RATIO; SILICON IMPLANTS; SILICONES;

CLINICAL APPLICATION; HIGH-RISK PATIENTS; MAGNETIC FIELD STRENGTHS; NEOADJUVANT CHEMOTHERAPIES; POTENTIAL BENEFITS; SAFETY CONSIDERATIONS; SPATIAL AND TEMPORAL RESOLUTIONS; UNKNOWN PRIMARRIES;

MEDICAL IMAGING;

EID: 84859789908     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511978968.005     Document Type: Chapter

References (20)

1. Rakow-Penner R, Daniel B, Yu H, Sawyer-Glover A, Glover GH. Relaxation times of breast tissue at 1.5T and 3T measured using IDEAL. J Magn Reson Imaging2006; 23: 87–91.
2. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol2005; 40: 715–24.
3. Barth MM, Smith MP, Pedrosa I, Lenkinski RE, Rofsky NM. Body MR imaging at 3.0 T: understanding the opportunities and challenges. Radiographics 2007; 27: 1445–62; discussion 1462–4.
4. Kuhl CK, Kooijman H, Gieseke J, Schild HH. Effect of B1 inhomogeneity on breast MR imaging at 3.0 T. Radiology2007; 244: 929–30.
5. Azlan CA, Di Giovanni P, Ahearn TS, et al.B1 transmission-field inhomogeneity and enhancement ratio errors in dynamic contrast-enhanced MRI (DCE-MRI) of the breast at 3T. J Magn Reson Imaging2010; 31: 234–9.
6. Kuhl CK, Jost P, Morakkabati N, et al.Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. Radiology2006; 239: 666–76.
7. Pinker K, Grabner G, Bogner W, et al.A combined high temporal and high spatial resolution 3Tesla MR imaging protocol for the assessment of breast lesions: initial results. Invest Radiol2009; 44: 553–8.
8. Wiesinger F, Van de Moortele PF, Adriany G, et al.Potential and feasibility of parallel MRI at high field. NMR Biomed2006; 19: 368–78.
9. Ladd ME. High-field-strength magnetic resonance: potential and limits. Top Magn Reson Imaging2007; 18: 139–52.
10. Rakow-Penner R, Hargreaves B, Glover GH, Daniel B. Breast MRI at 3T. Appl Radiol2009; 38(3): 6–13.
11. Guo Y, Cai YQ, Cai ZL, et al.Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging2002; 16: 172–8.
12. Woodhams R, Matsunaga K, Kan S, et al.ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci2005; 4: 35–42.
13. Partridge SC, DeMartini WB, Kurland BF, et al.Quantitative diffusion-weighted imaging as an adjunct to conventional breast MRI for improved positive predictive value. AJR Am J Roentgenol2009; 193: 1716–22.
14. Matsuoka A, Minato M, Harada M, et al.Comparison of 3.0- and 1.5-tesla diffusion-weighted imaging in the visibility of breast cancer. Radiat Med2008; 26: 15–20.
15. Lo GG, Ai V, Chan JK et al.Diffusion-weighted magnetic resonance imaging of breast lesions: first experiences at 3T. Comput Assist Tomogr2009; 33(1): 63–9.
16. Bolan PJ, Nelson MT, Yee D, Garwood M. Imaging in breast cancer: magnetic resonance spectroscopy. Breast Cancer Res2005; 7: 149–52.
17. Sinha S, Sinha U. Recent advances in breast MRI and MRS. NMR Biomed2009; 22: 3–16.
18. Haddadin IS, McIntosh A, Meisamy S, et al.Metabolite quantification and high-field MRS in breast cancer. NMR Biomed2009; 22: 65–76.
19. Meisamy S, Bolan PJ, Baker EH, et al.Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy – a pilot study at 4 T. Radiology2004; 233: 424–31.
20. Peters NH, Meeuwis C, Bakker CJ, et al.Feasibility of MRI-guided large-core-needle biopsy of suspiscious breast lesions at 3 T. Eur Radiol2009; 19: 1639–44.